Exploring the use of antisense therapy for neurodegenerative diseases: an interview with Frank Bennett

Written by Sharon Salt, Editor

Frank Bennett is the Senior Vice President at Ionis Pharmaceuticals (CA, USA). He is responsible for research at Ionis and is the Franchise Leader for Neurological Programs there, including both research and development activities within the neuro program. Dr Bennett has been with the company research programs for 29 years. What led to your interest in developing antisense oligonucleotides (ASOs) as therapeutic agents for neurodegenerative diseases? We’ve always had an interest in neurological diseases, however, when we first began and founded the company we felt that there were some questions we needed to address before we tackled neurological diseases. Thus,...

To view this content, please register now for access

It's completely free